Electronic supplementary material

ESM Table 1 Relative risk (95% CI) of developing type 2 diabetes, calculated by quintiles of IL-18 levels with additional adjustment for pro-inflammatory protein levels (in sub-sample)

Variables	Quintile of IL-18 concentration[a]					*p* value for trend
	1 (lowest)	2	3	4	5 (highest)	
Median (range)	160.1 (78.39–191.17)	215.2 (191.64–238.69)	260.4 (329.24–287.84)	329.3 (287.91–383.76)	462.5 (384.13–2100.63)	
Cases, *n* [b]	65	83	93	194	245	
Controls, *n* [b]	116	117	117	117	117	
Multivariate RR (95% CI) [c]	Referent	1.03 (0.74–1.43)	1.03 (0.75–1.42)	1.33 (1.00–1.78)	1.38 (1.04–1.83)	0.002
Multivariate RR (95% CI) [d]	Referent	1.03 (0.74–1.43)	1.04 (0.75–1.43)	1.31 (0.98–1.75)	1.34 (1.01–1.78)	0.03
Multivariate RR (95% CI) [e]	Referent	1.03 (0.74–1.42)	1.03 (0.75–1.42)	1.33 (1.00–1.78)	1.37 (1.02–1.82)	0.003
Multivariate RR (95% CI) [f]	Referent	1.04 (0.74–1.46)	1.05 (0.75–1.46)	1.35 (1.00–1.82)	1.40 (1.05–1.88)	0.001
Multivariate RR (95% CI) [g]	Referent	0.99 (0.71–1.38)	1.02 (0.73–1.42)	1.26 (0.93–1.71)	1.24 (0.92–1.67)	0.03

[a]Quintiles based on control distribution (in the sub-sample with CRP measured)
[b]Total numbers *n*=680 / 584 (cases/controls)
[c]Adjusted for (1) matching factors (age, date of blood draw, fasting status and ethnicity); (2) diabetes risk factors (physical activity in quintiles of MET /week, smoking [never, past, current 1–14 cigarettes/day and current ≥15 cigarettes/day], family history of diabetes [yes/no], hormone replacement therapy [premenopausal, never, past, current and information not available], alcohol consumption [non-drinkers, 0.1–4.9, 5–10 and >10 g/day], glycaemic load [quintiles], ratio of polyunsaturated : saturated fat [quintiles] and intake [quintiles] of cereal fibre, *trans* fat, magnesium and total energy); and (3) BMI by category (<23, 23–24.9, 25–26.9, 27–29.9, 30–34.9 and ≥35 kg/m^2)
[d]Adjusted as [c] above and additionally for CRP
[e]Adjusted as [c] above and additionally for TNFr2
[f]Adjusted as [c] above and additionally for IL-6
[g]Adjusted as [c] above and additionally for all biomarkers (HMW adiponectin, resistin, CRP, IL-6, TNFr2)